Korean drug makers get a win in generic Lipitor case

Published: 2007-08-14 06:59:00

Updated: 2007-08-14 06:59:00

Recently, a local Patent Trial Board ruled that a key patent that Pfizer holds on atorvastatin, the active ingredient in Lipitor, is invalid. The decision means that Pfizer's Korean patent on the drug, the world's top-selling prescription branded medication, is no longer viable.

The patent cha...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK